Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...

Dr. Reddy's Laboratories Ltd. closed 10.04% short of its 52-week high of 1,420.20 rupees, which the company achieved on August 21st.

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

Dr. Reddy's Laboratories has kicked off FY26 with double-digit growth. M.V. Ramana, CEO of Branded Markets (India & Emerging Markets), breaks down how the pharma major is evolving its strategy beyond ...

Dr. Reddy's Laboratories Limited RDY reported first-quarter fiscal 2026 earnings of 20 cents per American Depositary Share ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

HYDERABAD, India (AP) — HYDERABAD, India (AP) — Dr. Reddy's Laboratories Ltd. (RDY) on Wednesday reported profit of $165 million in its fiscal first quarter. On a per-share basis, the Hyderabad, India ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Dr Reddy's Laboratories posted a 1% rise in net profit to Rs 1,410 crore for the June quarter, with revenue climbing to Rs 8,545 crore. Growth stemmed from branded markets and the Nicotine Replacement ...

Dr Reddy's Laboratories reported a 1% rise in net profit for the June quarter, with revenues increasing from Rs 7,673 crore to Rs 8,545 crore. Despite facing pricing pressures in the US generic market ...

Dr. Reddy's Laboratories Ltd. closed 12.16% short of its 52-week high of 1,420.20 rupees, which the company reached on August 21st.